VKTX Stock Cash Flow Statements

Viking Therapeutics Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Viking Therapeutics Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31

cash flows from operating activities
net income	-65,561,000	-45,629,000	-35,417,000	-24,940,000	-22,250,000	-27,356,000	-24,605,000	-22,534,000	-19,225,000	-19,531,000	-19,559,000	-15,773,000	-17,432,000	-16,103,000	-12,356,000	-13,243,000	-15,381,000	-14,010,000	-10,948,000	-9,288,000	-9,572,000	-9,687,000	-7,450,000	-5,731,000	-7,674,000	-4,924,000	-5,240,000	-6,600,000	-6,672,000	-3,551,000	-4,084,473	-6,099,658	-5,171,634	-5,221,900	-3,644,609	-3,807,432	-3,692,793	-3,586,988	-5,090,963	-4,736,544	-7,865,066	-5,711,415
adjustments to reconcile net income to net cash from operating activities
amortization of investment premiums	-2,391,000	-3,133,000	-4,031,000	-4,979,000	-5,436,000	-2,821,000	-2,702,000	-3,145,000	-1,966,000	-389,000	-53,000	143,000	457,000	670,000	755,000	972,000							454,000				-71,000	-5,000	87,000	62,000	15,962	29,401	18,637	30,645	36,773	31,951	36,536	48,475	64,207	63,562
amortization of financing costs	24,000	24,000	24,000	24,000	18,000	28,000	26,000	2,000	32,000	28,000	8,000	27,000	12,000	12,000	12,000	-35,000	20,000	21,000	21,000	20,000	20,000	45,000	46,000	40,000	30,000	30,000	30,000	30,000	30,000	30,000	33,516	17,568	421,781	98,179	92,849
stock-based compensation	13,547,000	11,348,000	5,667,000	8,982,000	7,082,000	7,981,000	4,080,000	4,481,000	4,620,000	3,569,000	2,156,000	1,940,000	2,220,000	2,357,000	1,433,000	1,599,000	1,491,000	1,577,000	1,042,000	1,475,000	1,649,000	1,652,000	976,000	811,000	922,000	1,034,000	617,000	750,000	631,000	610,000	363,840	344,128	341,258	402,239	358,575	320,953	490,245	624,554	527,444	601,592	1,471,509	903
amortization of right-of-use assets	112,000	111,000	110,000	87,000	75,000	74,000	74,000	73,000	73,000	72,000	72,000	142,000	0	77,000	76,000	75,000	73,000	72,000	71,000	70,000	68,000	68,000
realized (gain) loss on investment
interest expense related to operating lease liability	8,000	10,000	11,000	9,000	9,000	9,000	10,000	10,000	11,000	12,000	12,000	25,000	0	4,000	0	2,000	4,000	5,000	7,000	7,000	8,000	10,000
changes in operating assets and liabilities:
prepaid expenses and other current assets	-5,089,000	-9,554,000	1,505,000	-2,728,000	-79,000	1,748,000	-58,000	1,373,000	7,351,000	-2,258,000	-1,432,000	823,000	-2,544,000	23,000	-307,000	1,254,000	-1,392,000	-266,000	112,000	-1,176,000	632,000	569,000	-6,670,000	-175,000	-610,000	75,000	1,686,000	-427,000	-1,080,000	-316,000	198,264	245,535	-167,483	221,310	181,200	108,227	-203,802	187,704	424,255	-912,432	-576,031	-15,564
accrued interest, net of interest receivable on maturity of investments	-11,000	2,470,000	-646,000	1,347,000	-157,000	655,000	-101,000	246,000
accounts payable	-2,209,000	-2,110,000	9,561,000	-10,835,000	5,864,000	-2,287,000	1,801,000	100,000	1,813,000	-4,732,000	5,387,000	-2,963,000	2,954,000	1,707,000	-1,390,000	-1,377,000	-637,000	860,000	1,230,000	-452,000	127,000	650,000	343,000	219,000	194,000	716,000	-175,000	-330,000	829,000	-832,000	31,385	174,971	-465,782	522,935	376,825	-102,088	-47,253	449,701	81,951	92,849	7,131	37,306
accrued expenses	14,643,000	-5,739,000	-7,836,000	11,280,000	-13,551,000	15,923,000	3,922,000	-177,000	-3,989,000	-1,572,000											-356,000	1,840,000	519,000	1,283,000	710,000	-118,000	337,000	1,015,000	544,000	-428,000	-477,484	318,488	696,814	472,143	281,704	252,381	77,300	-752,680	315,584	1,052,508	129,280	62,707
lease liability	-130,000	-129,000	-128,000	-96,000	-90,000	-88,000	-87,000	-87,000	-88,000	-85,000	-84,000	-112,000	83,000	-76,000	-86,000	-85,000	-86,000	-85,000	-85,000	-83,000	-82,000	-83,000
net cash from operating activities	-47,061,000	-52,331,000	-31,181,000	-21,962,000	-28,513,000	-6,134,000	-17,640,000	-19,658,000	-11,435,000	-24,643,000	-10,926,000	-13,499,000	-13,442,000	-10,530,000	-12,350,000	-10,926,000	-13,434,000	-10,876,000	-5,486,000	-5,323,000	-6,666,000	-4,302,000	-11,743,000	-3,398,000	-6,459,000	-3,152,000	-2,679,000	-5,503,000	-5,270,000	-5,303,000	-3,948,002	-3,328,003	-4,203,170	-3,278,592	-2,464,884	-2,654,415	-3,226,840	-2,725,124	-3,299,390	-3,400,454	-1,620,709	-410,941
cash flows from investing activities
purchases of investments	-123,476,000	-232,614,000	-136,960,000	-149,985,000	-229,822,000	-596,601,000	-97,533,000	-79,399,000	-243,976,000	-57,395,000	-44,606,000	-10,445,000	-35,698,000	-30,682,000	-35,570,000	-24,167,000	-59,602,000	-48,676,000	-32,963,000	-108,682,000	-82,556,000	-56,435,000	-80,048,000	-99,474,000	-83,666,000	-99,218,000	-180,914,000	-53,583,000	-81,428,000	-32,279,000	-9,419,476	-2,680,171	-4,368,643	-6,057,417	-4,658,784	-2,016,972	-10,097,119	-149,360	0	-3,858,975
proceeds from maturities of investments	165,982,000	295,859,000		175,886,000	103,763,000	136,809,000						37,339,000	54,678,000	32,301,000		37,784,000	63,162,000	42,049,000		99,048,000	92,336,000	67,587,000		114,628,000	94,645,000	91,609,000		26,497,000	14,803,000	2,652,000
net cash from investing activities	42,506,000	63,245,000	6,584,000	25,901,000	-126,059,000	-459,792,000	35,733,000	-12,534,000	-204,483,000	2,198,000	7,260,000	26,894,000	18,980,000	1,619,000	27,410,000	13,617,000	3,560,000	-6,627,000	30,269,000	-9,634,000	9,780,000	11,152,000	-11,061,000	15,154,000	10,979,000	-7,609,000	-142,391,000	-27,086,000	-66,625,000	-29,627,000	-4,395,476	1,391,829	-764,643	2,038,583	1,447,216	441,028	-4,831,119	5,972,640	1,956,000	-3,251,975
cash flows from financing activities
public offering, net of offering costs			0	0	-25,000	597,119,000	0	-73,000
value of shares withheld related to employee tax withholding			0	0	0	-42,101,000	0	0	-5,407,000	-1,714,000	-1,034,000	0	0	-499,000	0	-234,000	0	-473,000	0	-169,000	0	-127,000	-27,000	-2,000	-38,000	-84,000	-26,000	-2,000			-7,628	-213			-5,210	-2,092			0	0
proceeds from exercises of stock options and other stock issuances	507,000	349,000
atm offering, net of fees			0	0	0	46,658,000	0	0	0	1,969,000
net cash from financing activities	507,000	349,000	1,000,000	2,522,000	2,905,000	606,037,000	188,000	-74,000	267,078,000	4,184,000	10,749,000	10,000	-1,590,000	-5,006,000	47,000	-256,000	1,898,000	5,191,000	464,000	37,000	416,000	33,000	229,000	73,000	260,000	325,000	343,000	167,485,000	70,149,000	62,298,000	14,763,893	1,110,586	4,002,418	2,523,553	1,038,278	108,349	9,259,126	-57,303	-28,175	-704,656	22,964,969	-17,909
net increase in cash and cash equivalents	-4,048,000	11,263,000	-23,597,000	6,461,000	-151,667,000	140,111,000	18,281,000	-32,266,000			7,083,000				15,107,000	2,435,000	-7,976,000	-12,312,000	25,247,000	-14,920,000	3,530,000	6,883,000	-22,575,000	11,829,000	4,780,000	-10,436,000	-144,727,000	134,896,000	-1,746,000	27,368,000	6,420,415	-825,588	-965,395	1,283,544	20,610	-2,105,038	1,201,167	3,190,213	-1,371,565	-7,357,085
cash and cash equivalents beginning of period	0	26,676,000	0	0	0	55,516,000	0	0	0	36,632,000	0	0	0	26,371,000	0	0	0	29,117,000	0	0	0	8,377,000	0	0	0	24,779,000	0	0	0	8,988,000	0	0	0	3,075,502	0	0	0	768,550	0
effect of exchange rate changes on cash	-12,000	1,000	-74,000	-29,000	3,000	-48,000	50,000	-68,000	-3,000	-9,000	141,000	-223,000
cash and cash equivalents end of period	-4,060,000	37,940,000	-23,671,000	6,432,000	-151,664,000	195,579,000	18,331,000	-32,334,000	51,157,000	18,362,000	7,224,000	13,182,000	3,772,000	12,454,000	15,107,000	2,435,000	-7,976,000	16,805,000	25,247,000	-14,920,000	3,530,000	15,260,000	-22,575,000	11,829,000	4,780,000	14,343,000	-144,727,000	134,896,000	-1,746,000	36,356,000	6,420,415	-825,588	-965,395	4,359,046	20,610	-2,105,038	1,201,167	3,958,763	-1,371,565
supplemental disclosure of non-cash investing and financing transactions
unpaid deferred public offering and other financing costs	0	50,000	0	-25,000	6,000	69,000	0	16,000	-18,000	52,000	6,000	-25,000	0	50,000	-19,000	19,000	0	50,000	0	0	-16,000	66,000	-8,000					-26,000	173,000	136,000	-79,924	71,705	131,749	16,055
realized gain on investment			-1,000	-113,000
proceeds from sales and maturities of investments							133,266,000	66,865,000	39,493,000	59,593,000																							3,604,000	8,096,000	6,106,000	2,458,000	5,266,000	6,122,000	1,956,000
repurchase of common stock											0	0	-1,674,000	-5,121,000
proceeds from warrant and option exercises and stock issuances under employee stock purchase plan							188,000	-1,000	2,615,000	3,966,000	150,000	0	84,000	614,000		5,000	1,898,000	5,664,000		206,000	442,000	160,000
right-of-use asset obtained in exchange for lease obligation			0								0	0	0	1,664,000
proceeds from option exercises and employee stock purchase plan common stock issuance				2,522,000
proceeds from option exercises						4,361,000
realized loss on investment												0
accrued interest, net of interest received on maturity of investments										243,000	115,000	151,000	243,000	105,000	594,000	-11,000	759,000	-166,000	673,000
public offering and financing costs										-37,000					-19,000				0	0			-7,000				-283,000	-216,000	-120,000	-146,000	-376,272	-61,940	-46,055	-15,990	-71,624
net decrease in cash and cash equivalents										-18,261,000			3,948,000	-13,917,000
amortization of non-cash clinical trial costs																							0	0	6,000	134,000	125,000	64,000	252,000	225,000	345,464	248,894	357,259	42,328
realized gain on investments																			-26,000
other accrued liabilities												2,098,000	523,000	694,000		-77,000	674,000	-22,000
public offering and finance costs
receivable from exercise of warrants																		173,000
proceeds from stock issuance under employee stock purchase plan and warrant exercises
amortization of investment premiums (accretion of investment discounts)																		1,138,000		1,078,000	853,000	636,000			-37,000	-101,000
realized (gain) loss on investments																					-13,000	-2,000
amortization of debt discount on notes payable																											0	0	146,000	258,000	258,152	256,596	336,656	431,227	431,227	431,227	524,977	400,657	240,516	240,515
change in fair value of debt conversion feature liability																											0	0	-37,000	-1,361,000	-632,628	1,136,074	-570,676	-277,698	-620,087	64,514	-412,050	-96,547	216,841	197,496	546,485	82,656
proceeds from issuances of common stock, net of underwriting discounts and commissions																											0	165,205,000	72,580,000	58,822,000	14,519,612	1,250,000	4,042,735	2,539,543	1,103,996	525,772
repayment of convertible notes payable																											0	0			0				0	0
supplemental disclosure of cash flow information:
cash paid during the period for interest																											0	0			0				0	0
realized loss on investments																									0	2,000
proceeds from warrant and option exercises and stock issuance under employee stock purchase plan																									298,000	409,000		2,498,000
deposits
shares issued to cover future clinical trial costs																															0	0	0	1,800,000
shares issued as commitment fee in connection with lincoln park agreement																															0
proceeds from warrant and option exercises																														3,622,000
repurchases of common stock																																							0
shares issued as commitment fee in connection with aspire agreement																																			0
shares issued in lieu of loan payment to related party																																			0	0
proceeds from stock issuance under employee stock purchase plan																																0			11,345	0			20,489	0
change in fair value of accrued license fees																																							0	0	4,421,337	4,960,511
shares issued in lieu of license fee payment
conversion of notes payable																																							0	0
issuance of common stock to consultant																																							0	57,520
shares issued in lieu of license fee payment to related party
public offering costs																																					-551,947	-57,303	-48,664	-704,656
unpaid deferred public offering costs																																					-27,423	409,414
accounts payable - related party
accrued license fees
proceeds from convertible notes payable
issuance of common stock in exchange for notes receivable
net proceeds from issuances of common stock																																								0
shares issued in lieu of license fee																																								58,495,422
unpaid deferred ipo costs
cash, and cash equivalents beginning of period
cash, and cash equivalents end of period
amortization of discount charged to interest expense on convertible notes																																										171,955
deferred ipo financing costs paid																																										-17,909
net increase in cash																																										-428,850
cash, beginning of period																																										755,857
cash, end of period																																										327,007
deferred ipo costs included in accounts payable and accrued expenses																																										2,057,903
•

We provide you with 20 years of cash flow statements for Viking Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Viking Therapeutics stock. Explore the full financial landscape of Viking Therapeutics stock with our expertly curated income statements.

The information provided in this report about Viking Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.